ONWARD2
23 evidence topics · 6 sources
Objective
Objective in the brief title of the ClinicalTrials.gov record
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Study start (actual) | “2024-08-20” |
| Primary completion (actual) | “2025-09-23” |
| Study completion (actual) | “2025-12-18” |
| First submitted | “2024-09-07” |
| Last update posted | “2026-10-28” |
Completion dates estimated at registration, September 2024, superseded in June 2025
| Field | Quoted record |
|---|---|
| Primary completion | “2026-05 [Estimated]” |
| Study completion | “2026-06 [Estimated]” |
Results posting status and certification date in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Results | “No Results Posted” |
| Certification/extension first submitted | “2026-08-06” |
Countries of trial sites in the ClinicalTrials.gov record
| Country | First site listed for the country in the record |
|---|---|
| United States | “Birmingham, Alabama, United States, 35203” |
| Austria | “Vienna, Austria, 1220” |
| Canada | “Calgary, Alberta, Canada, T3E 0B2” |
| Estonia | “Tallinn, Estonia, 10128” |
| France | “Nice, France, 06000” |
| Germany | “Berlin, Germany, 10789” |
| Hungary | “Budapest, Hungary, 1152” |
| Israel | “Ramat Gan, Israel, 526200” |
| Latvia | “Riga, Latvia, LV1001” |
| Poland | “Katowice, Poland, 40-568” |
| Puerto Rico | “Caguas, Puerto Rico, 00725” |
| Spain | “Alicante, Spain, 3010” |
Countries listed for ESK-001-017 in the topline webcast presentation
Study design
Design in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Age and sex | “Males or females, age ≥18 years” |
| Disease duration | “Diagnosis of plaque psoriasis for ≥6 months” |
| Body surface area | “Plaques covering ≥10% of BSA” |
| PASI | “PASI ≥12” |
| sPGA | “sPGA ≥3” |
| Contraception | “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception” |
Exclusion criteria on psoriasis type, associated conditions, and pregnancy in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Psoriasis type | “Nonplaque psoriasis or other inflammatory skin conditions” |
| Associated immune-mediated conditions | “Immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Patients with psoriatic arthritis may participate” |
| Pregnancy | “Pregnant, lactating, or planning to get pregnant during the study” |
Washout periods and prior treatment response in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Topical therapy | “Topical within 2 weeks” |
| Phototherapy or systemic therapy | “Phototherapy or any systemic treatments within 4 weeks” |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months” |
| Systemic immunosuppressants | “Systemic immunosuppressants or immunomodulatory drugs within 4 weeks” |
| B-cell and T-cell modulators | “Modulators of B cells within 6 months, or T cells within 3 months” |
| JAK and TYK2 inhibitors | “JAK inhibitors or TYK2 inhibitors within 4 weeks” |
| PDE4 inhibitors | “PDE4 inhibitor within 2 months” |
| Investigational agents | “Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study” |
| Prior treatment response | “Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment” |
Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in October 2024
| Criterion | Quoted record |
|---|---|
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic or oral agent targeted to IL-12 or IL-23 within 6 months or any TNFα inhibitor within 2 months or IL-17 within 4 months” |
Cardiac, infection, laboratory, and corticosteroid exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Quoted record |
|---|---|
| Experimental: ESK-001 | “ESK-001 administered as an oral tablet” |
| Placebo comparator | “Matching oral placebo” |
| Active comparator: apremilast | “Apremilast administered as an oral capsule” |
Study outcomes
Rationale for using PASI 75 and sPGA 0/1 response as the co-primary endpoints
Primary outcome in the ClinicalTrials.gov record
Secondary outcomes in the ClinicalTrials.gov record
Regulatory guidance on the clinical meaning of PASI 75 response and on global assessment scales
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Planned enrollment at registration
| Field | Quoted record |
|---|---|
| Enrollment | “840 [Estimated]” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Baseline demographics and disease characteristics by arm in ONWARD2
| Characteristic | Envudeucitinib 40 mg BID, n = 433 | Placebo, n = 211 | Apremilast 30 mg BID, n = 215 |
|---|---|---|---|
| Age, years, mean (SD) | “48.3 (13.1)” | “49.5 (13.3)” | “48.0 (12.8)” |
| Age group, ≥65 years, n (%) | “51 (11.8)” | “28 (13.3)” | “20 (9.3)” |
| Sex, male, n (%) | “283 (65.4)” | “135 (64.0)” | “135 (62.8)” |
| Race, White, n (%) | “388 (89.6)” | “181 (85.8)” | “193 (89.8)” |
| Race, Asian, n (%) | “10 (2.3)” | “10 (4.7)” | “7 (3.3)” |
| Race, other, n (%) | “35 (8.1)” | “20 (9.5)” | “15 (7.0)” |
| Weight, kg, mean (SD) | “92.3 (23.8)” | “91.1 (23.1)” | “90.8 (19.9)” |
| BMI, kg/m2, mean (SD) | “31.2 (7.8)” | “31.1 (7.3)” | “30.9 (5.9)” |
| Duration of disease, years, mean (SD) | “19.0 (13.5)” | “20.2 (14.5)” | “18.7 (14.5)” |
| PASI, mean (SD) | “20.6 (8.3)” | “21.8 (9.0)” | “20.4 (8.4)” |
| sPGA of 4, n (%) | “131 (30.3)” | “70 (33.2)” | “53 (24.7)” |
| BSA % affected, mean (SD) | “25.2 (14.7)” | “27.3 (16.7)” | “25.8 (14.1)” |
| DLQI, mean (SD) | “10.8 (7.0)” | “10.8 (6.8)” | “9.7 (7.1)” |
| Worst pruritus NRS, mean (SD) | “6.4 (2.6)” | “6.4 (2.4)” | “6.0 (2.7)” |
| Prior systemic psoriasis treatment, n (%) | “213 (49.2)” | “105 (49.8)” | “102 (47.4)” |
Baseline itch and scalp involvement by arm in ONWARD2
| Characteristic | Envudeucitinib 40 mg BID, N = 433 | Placebo, N = 211 | Apremilast 30 mg BID, N = 215 |
|---|---|---|---|
| Worst pruritus NRS ≥1, n (%) | “400 (92.4)” | “200 (94.8)” | “199 (92.6)” |
| Worst pruritus NRS ≥4, n (%) | “345 (79.7)” | “180 (85.3)” | “170 (79.1)” |
| ss-PGA ≥3, n | “285” | “140” | “134” |
| Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%) | “231 (81.1)” | “122 (87.1)” | “108 (80.6)” |
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- ONWARD2-specific results are limited to baseline characteristics and PASI 75, PASI 90, and PASI 100 rates at weeks 16 and 24 in one congress presentation. The report holds no description of the ONWARD2 analysis sets, participant disposition, patient-reported outcomes, or safety for ONWARD2 alone, and no ONWARD2 sPGA 0/1 rate.
- The ClinicalTrials.gov record gives an actual enrollment of 862 participants; the congress presentation gives arm sizes of 433, 211, and 215.
- The ClinicalTrials.gov record reads “No Results Posted”, with a certification/extension first submitted on 2026-08-06.
- Asian participants made up 10 (2.3%), 10 (4.7%), and 7 (3.3%) of the envudeucitinib, placebo, and apremilast arms, and White participants 388 (89.6%), 181 (85.8%), and 193 (89.8%).
- Baseline sPGA of 4 was recorded in 131 (30.3%), 70 (33.2%), and 53 (24.7%) participants of the envudeucitinib, placebo, and apremilast arms, and mean baseline PASI was 20.6, 21.8, and 20.4.